Introduction
n Head and neck cancers, originating from the upper aero-digestive tract, are amongst the top ten malignancies globally for both incidence and mortality [1] .
n The most recent National audit found that over 8,300 people were diagnosed with head and neck cancer between November 2012 and October 2013, in England and Wales. The majority of these diagnoses were found to be squamous cell carcinomas (SCCs) of the oral cavity, oropharynx and larynx [2] .
n The recent rise in oropharyngeal cases in countries such as England and Wales [2, 3] 
Methods
n A retrospective analysis was performed using data extracted from Hospital Episode Statistics (HES).
n Inpatient and outpatient records with diagnosis fields featuring ICD-10 codes for oropharyngeal, laryngeal and oral cavity cancers (see Table 1 ) were extracted for the years 2006/07 to 2010/11.
n As 2010/11 was representative of nine months provisional data, a correction factor was applied to inflate the figures to cover an entire year.
n After grouping inpatient episodes into spells, a single Healthcare Resource Group (HRG) was derived for each and then cross-referenced with the National Tariff 2010/11 [6] to estimate the associated cost.
n HRG4 allows for the unbundling of certain costs from the National Tarriff (for more information on unblunding see [7] ). Therefore, bundled costs and unbundled costs were analysed.
n Outpatient costs were estimated by grouping consultations by treatment speciality based on Treatment Function Codes (TFCs) and whether the consultation was the first of a series or a follow-up.
n Limitations include HES limitations such as miscoding and gaps in the HES outpatient dataset.
Results
n The total costs of treatment for patients across all three sites were estimated to be around £309 million, at 2011 prices.
n Costs due to oropharyngeal cancer were slightly higher than for the other two sites (£115 million; 37.06%), with laryngeal and oral cavity cancer accounting for 31.15% (£96 million) and 31.79% (£98 million), respectively.
n Males were responsible for nearly three quarters (73.64%; £227.77 million) of total treatment costs ( Table 2) .
Both costs and patient numbers were seen to be rising over time (Figure1).
n Total costs increased from £53.17 million in 2006/07 to £73.58 million in 2010/11, a rise of 38%.
n The annual number of inpatients jumped from 8,890 to 11,185 over the same period (25% increase). 
n Much of the overall rise was found to be driven by oropharyngeal cancer, where the total costs increased from £17.21 million to £30.32 million, a rise of 76%, with over 1400 (52%) more inpatients treated in 2010/11 compared to 2006/07 (Figure 2 ).
n The total costs for laryngeal and oral cavity cancer grew by 19% and 22%, respectively over the course of the study, with inpatient numbers also increasing by 372 (13%) and 502 (15%) (Figure 2 ).
Conclusions
n The results of this analysis show that there is a significant health and economic burden associated with oropharyngeal, laryngeal and oral cavity cancers in England.
n A sizeable increase in oropharyngeal patient numbers and cost was observed over the period.
n Limitations of HES, such as erroneous clinical coding and an immature outpatient data, mean that the results are most likely an underestimate of the burden of oropharyngeal, laryngeal and oral cavity cancers.
n Sustained pressure on NHS resources requires strategic investment for both treatment and prevention of these diseases. £20,000,000 £15,000,000 £10,000,000 £5,000,000
